{
    "info": {
        "nct_id": "NCT03734016",
        "official_title": "A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
        "inclusion_criteria": "Key Inclusion Criteria\n\n1. Confirmed diagnosis of CLL or SLL that meets the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria\n2. CLL/SLL requiring treatment per 2008 IWCLL criteria\n3. Relapsed or refractory to at least 1 prior systemic therapy for CLL/SLL\n4. Measurable disease by computerized tomography (CT)/magnetic resonance imaging (MRI)\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2\n6. Life expectancy ≥ 6 months\n7. Adequate bone marrow function\n8. Adequate renal and hepatic function\n\nKey Exclusion Criteria\n\n1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation\n2. Clinically significant cardiovascular disease.\n3. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast\n4. History of severe bleeding disorder or history of spontaneous bleeding requiring blood transfusion or other medical intervention\n5. History of stroke or intracranial hemorrhage within 180 days before first dose of study drug\n6. Severe or debilitating pulmonary disease\n7. Active fungal, bacterial, and/or viral infection requiring systemic therapy\n8. Known central nervous system involvement by leukemia or lymphoma\n9. Known infection with HIV or active viral hepatitis B or C infection\n10. Moderate or severe hepatic impairment, ie, Child-Pugh class B or C\n11. Major surgery within 4 weeks of the first dose of study drug\n12. Prior treatment with a (Burton's Kinase) BTK inhibitor\n13. Toxicity from prior anticancer therapy that has not recovered to ≤ Grade 1\n14. Pregnant or lactating women\n15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug\n16. Hypersensitivity to zanubrutinib, ibrutinib, or any of the other ingredients in either drug\n17. Concurrent participation in another therapeutic clinical trial\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. CLL/SLL requiring treatment per 2008 IWCLL criteria",
            "criterions": [
                {
                    "exact_snippets": "CLL/SLL requiring treatment per 2008 IWCLL criteria",
                    "criterion": "chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "CLL",
                                "SLL"
                            ]
                        },
                        {
                            "requirement_type": "treatment indication (per 2008 IWCLL criteria)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Relapsed or refractory to at least 1 prior systemic therapy for CLL/SLL",
            "criterions": [
                {
                    "exact_snippets": "Relapsed or refractory to at least 1 prior systemic therapy for CLL/SLL",
                    "criterion": "CLL/SLL",
                    "requirements": [
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        },
                        {
                            "requirement_type": "prior_systemic_therapy_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "prior systemic therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Measurable disease by computerized tomography (CT)/magnetic resonance imaging (MRI)",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease by computerized tomography (CT)/magnetic resonance imaging (MRI)",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computerized tomography (CT)",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Life expectancy ≥ 6 months",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Adequate bone marrow function",
            "criterions": [
                {
                    "exact_snippets": "Adequate bone marrow function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate renal and hepatic function",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Confirmed diagnosis of CLL or SLL that meets the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria",
            "criterions": [
                {
                    "exact_snippets": "Confirmed diagnosis of CLL or SLL",
                    "criterion": "diagnosis of CLL or SLL",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meets the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria",
                    "criterion": "IWCLL 2008 criteria for CLL/SLL",
                    "requirements": [
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation",
            "criterions": [
                {
                    "exact_snippets": "Known prolymphocytic leukemia",
                    "criterion": "prolymphocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "history or presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... Richter's transformation",
                    "criterion": "Richter's transformation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "currently suspected, Richter's transformation",
                    "criterion": "Richter's transformation",
                    "requirements": [
                        {
                            "requirement_type": "current suspicion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Clinically significant cardiovascular disease.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast",
            "criterions": [
                {
                    "exact_snippets": "Prior malignancy within the past 3 years",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of severe bleeding disorder or history of spontaneous bleeding requiring blood transfusion or other medical intervention",
            "criterions": [
                {
                    "exact_snippets": "History of severe bleeding disorder",
                    "criterion": "severe bleeding disorder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of spontaneous bleeding requiring blood transfusion or other medical intervention",
                    "criterion": "spontaneous bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "required intervention",
                            "expected_value": [
                                "blood transfusion",
                                "other medical intervention"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. History of stroke or intracranial hemorrhage within 180 days before first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "History of stroke ... within 180 days before first dose of study drug",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days before first dose of study drug"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intracranial hemorrhage within 180 days before first dose of study drug",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 180,
                                "unit": "days before first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Severe or debilitating pulmonary disease",
            "criterions": [
                {
                    "exact_snippets": "Severe or debilitating pulmonary disease",
                    "criterion": "pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "severe",
                                "debilitating"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Active fungal, bacterial, and/or viral infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Active fungal ... infection requiring systemic therapy",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active ... bacterial ... infection requiring systemic therapy",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active ... viral infection requiring systemic therapy",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Known central nervous system involvement by leukemia or lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Known central nervous system involvement by leukemia or lymphoma",
                    "criterion": "central nervous system involvement by leukemia or lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Major surgery within 4 weeks of the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of the first dose of study drug",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Moderate or severe hepatic impairment, ie, Child-Pugh class B or C",
            "criterions": [
                {
                    "exact_snippets": "Moderate or severe hepatic impairment, ie, Child-Pugh class B or C",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "Child-Pugh class",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Prior treatment with a (Burton's Kinase) BTK inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with a (Burton's Kinase) BTK inhibitor",
                    "criterion": "prior treatment with BTK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Toxicity from prior anticancer therapy that has not recovered to ≤ Grade 1",
            "criterions": [
                {
                    "exact_snippets": "Toxicity from prior anticancer therapy that has not recovered to ≤ Grade 1",
                    "criterion": "toxicity from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Pregnant or lactating women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating women",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Hypersensitivity to zanubrutinib, ibrutinib, or any of the other ingredients in either drug",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity to zanubrutinib",
                    "criterion": "hypersensitivity to zanubrutinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity to ... ibrutinib",
                    "criterion": "hypersensitivity to ibrutinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hypersensitivity to ... any of the other ingredients in either drug",
                    "criterion": "hypersensitivity to other ingredients in zanubrutinib or ibrutinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol defined Inclusion/Exclusion criteria may apply.",
                    "criterion": "other protocol defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug",
            "criterions": [
                {
                    "exact_snippets": "Vaccination with a live vaccine within 35 days prior to the first dose of study drug",
                    "criterion": "live vaccine vaccination",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 35,
                                "unit": "days prior to first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Concurrent participation in another therapeutic clinical trial",
            "criterions": [
                {
                    "exact_snippets": "Concurrent participation in another therapeutic clinical trial",
                    "criterion": "participation in another therapeutic clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Key Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "Key Exclusion Criteria",
            "criterions": []
        },
        {
            "line": "9. Known infection with HIV or active viral hepatitis B or C infection",
            "criterions": [
                {
                    "exact_snippets": "Known infection with HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active viral hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active viral hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}